Instituto de Diagnóstico e Investigaciones Metabólicas (IDIM)
Hospital
Location:
Buenos Aires,
Argentina (AR)
ISNI: -
ROR: https://ror.org/01rqa5h24
Show on Map:
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial (2021)
Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, Nogues X, et al.
Journal article
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial (2017)
Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, et al.
Journal article
Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab (2014)
Keaveny TM, Mcclung MR, Genant HK, Zanchetta JR, Kendler D, Brown JP, Goemaere S, et al.
Journal article